Arcosa, Inc.
No enriched coverage for $ACA in the last 7 days.
No SEC Form 4 filings for $ACA in the last 30 days.
See all $ACA insider activity →Arcosa (NYSE: ACA) will start quarterly bondholder calls for its senior notes, beginning with Q2 2026 results. The calls cover $400M 4.375% notes due 2029 and $600M 6.875% notes due 2032. Shareholders approved its $150/share acquisition by CRH (NYSE: CRH), expected to close in Q1 2027.
Arcosa (ACA) shares fell as doubts grew about its $8.5B sale to CRH, following a UBS note lowering CRH's price target and warning about infrastructure funding risks. Arcosa's stock trades below the $150 per share buyout price, and concerns about CRH's funding and deal fatigue are weighing on investor confidence. Despite improved profitability, Arcosa's recent revenue growth pause and softer cash conversion raise concerns about earnings durability.
Arcosa (ACA) reaffirmed its quarterly dividend of $0.05 per share, payable in October 2026. The stock has seen a 52.56% total return over the past year, with shares trading near analyst price targets. Analysts expect $2.6 billion in revenue and $248.1 million in earnings by 2029, with a PE ratio of 38.0x. The stock trades at 32.4x earnings, higher than peers, raising valuation concerns.
Recent ACA coverage spans mergers & acquisitions, corporate actions and market movers.
ACA shares likely face downward pressure as the all‑cash acquisition price is set, limiting upside.
Potential deal uncertainty could keep ACA below the agreed acquisition price, pressuring the stock.
The dividend reaffirmation may provide modest support to the stock price and attract income-focused investors.
Deal approval reduces uncertainty, likely supporting ACA share price and enabling CRH to proceed toward a 2027 close.
Deal approval removes uncertainty and sets path to a cash transaction at $150 per share.
AlphAI scores every news story that mentions ACA with an AI model for sentiment and relevance, and aggregates insider trades from Arcosa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcosa (NYSE: ACA) will start quarterly bondholder calls for its senior notes, beginning with Q2 2026 results. The calls cover $400M 4.375% notes due 2029 and $600M 6.875% notes due 2032. Shareholders approved its $150/share acquisition by CRH (NYSE: CRH), expected to close in Q1 2027.
2 min readArcosa (ACA) shares fell as doubts grew about its $8.5B sale to CRH, following a UBS note lowering CRH's price target and warning about infrastructure funding risks. Arcosa's stock trades below the $150 per share buyout price, and concerns about CRH's funding and deal fatigue are weighing on investor confidence. Despite improved profitability, Arcosa's recent revenue growth pause and softer cash conversion raise concerns about earnings durability.
2 min readArcosa (ACA) reaffirmed its quarterly dividend of $0.05 per share, payable in October 2026. The stock has seen a 52.56% total return over the past year, with shares trading near analyst price targets. Analysts expect $2.6 billion in revenue and $248.1 million in earnings by 2029, with a PE ratio of 38.0x. The stock trades at 32.4x earnings, higher than peers, raising valuation concerns.
2 min readArcosa, Inc. (ACA) shareholders approved an $8.5B acquisition by CRH plc (CRH) at $150 per share. The vote had 80.8% participation, with 39.6M votes in favor. CRH expects the deal to close in Q1 2027, pending regulatory approvals. CRH values the deal at 11.5x estimated 2026 adjusted EBITDA, with $175M in annual cost synergies expected by year three.
2 min readArcosa (ACA) stockholders approved the acquisition by CRH (CRH) for $150 per share. The deal, expected to close in Q1 2027, is subject to regulatory approvals. Arcosa is an infrastructure products and solutions provider with segments in Construction Products and Engineered Structures.
2 min readCredit Agricole SA (ACA.PA, CDA.L) appointed Larysa Bondarieva as CEO of Crédit Agricole Ukraine, effective September 4, 2026. She succeeds Carlos de Cordoue, who is retiring after 40 years with the group. Bondarieva has 30 years of banking experience, including senior roles at Crédit Agricole Ukraine.
1 min readArcosa Inc (ACA) shareholders approved its acquisition by CRH for $150 per share, pending regulatory approval. ACA's stock is 46.2% overvalued per GF Value™ at $145.45 vs. intrinsic value of $99.52. CRH's acquisition is expected to close in Q1 2027. ACA's GF Score™ is 76/100, with strong momentum and profitability but weak valuation. 9 gurus hold ACA, with 8 adding positions.
3 min readArcosa stockholders approved a $150-per-share cash acquisition by CRH. The transaction, expected to close in Q1 2027, requires regulatory approvals. Arcosa operates in infrastructure-related products and engineered structures.
1 min readArcosa (ACA) held a special meeting on September 4, 2026, where shareholders overwhelmingly approved a merger agreement with CRH Americas. 80.8% of shares voted, with 99.8% supporting the deal. Shareholders also approved executive compensation related to the merger on an advisory basis.
2 min readArcosa, Inc. (ACA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 4, 2026, Arcosa, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) at which the Company’s stockholders considered certain proposals related to the Agreement and Plan of M
1 min read
